Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.

AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View

Citigroup

Enterprise Products Partners

General Mills

Coca-Cola

Lockheed Martin

McDonald's

This article will give you seven of the most popular dividend stocks ranked from the largest market cap to the smallest. Dividend stocks have a place in every investor's portfolio.

The 7 Most Popular Dividend Stocks Ranked from Biggest to Smallest

AbbVie Inc. (NYSE:ABBV ) Q3 2022 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Liz Shea – Vice President-Investor Relations Rick Gonzalez – Chairman of the Board and Chief Executive Officer Jeff Stewart – Executive Vice President and Chief Commercial Officer Tom Hudson – Senior Vice President, R&D and Chief Scientific Officer Rob Michael – Vice Chairman and President Roopal Thakkar – Vice President, Global Regulatory Affairs Neil Gallagher – Vice President, Development and Chief Medical Officer Conference Call Participants Chris Schott – JPMorgan Tim Anderson – Wolfe Research Mohit Bansal – Wells Fargo Terence Flynn – Morgan Stanley Andrew Baum – Citigroup Global Steve Scala – Cowen Gary Nachman – BMO Capital Markets Colin Bristow – UBS Chris Shibutani – Goldman Sachs Geoff Meacham – Bank of America Liz Shea Good morning, and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Rob Michael, Vice Chairman and President; Jeff Stewart, Executive Vice President, Chief Commercial Officer; and Tom Hudson, Senior Vice President, R&D and Chief Scientific Officer.

AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript

AbbVie (ABBV) delivered earnings and revenue surprises of 2.81% and 0.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q3 Earnings Beat Estimates

AbbVie stock skidded Friday after the company reported mixed earnings and narrowed its full-year adjusted earnings outlook. The post AbbVie Skids On Mixed Earnings Report, Narrowed 2022 Earnings View appeared first on Investor's Business Daily.

AbbVie Skids On Mixed Earnings Report, Narrowed 2022 Earnings View

Genmab - ADR

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

European Medicines Agency (EMA) validates AbbVie's Marketing Authorization Application; Genmab submits Biologics License Application to U.S. Food and Drug Administration (FDA) The submissions are supported by the EPCORE™ NHL-1 open-label, multi-center Phase 2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill. , Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)

Shares of AbbVie Inc. ABBV, +0.65% fell 2.9% in premarket trading on Friday after the company trimmed guidance for adjusted earnings per share for the year. AbbVie had earnings of $3.9 billion, or $2.21 per share, in the third quarter of 2022, compared with $3.2 billion, or $1.78 per share, in the same quarter a year ago.

AbbVie narrows guidance for 2022

Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1 Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent

AbbVie Reports Third-Quarter 2022 Financial Results

AbbVie shares have been a bright spot in a dim market year-to-date, up a double-digit 17% and easily crushing the S&P 500's performance.

AbbVie Q3 Preview: Can Shares Continue Their Run?

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?

Brookfield Renewable Partners

Easterly Government Properties

The future looks bright for these stocks that offer attractive dividends.

3 Top Dividend Stocks to Buy and Hold in 2023

Data illustrates AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet need Oral presentations address treatment of moderate to severe Crohn's disease, including efficacy and safety outcomes from the SKYRIZI® (risankizumab-rzaa) pivotal clinical program as well as late-breaking Phase 3 investigational data from the upadacitinib 52-week maintenance trial Poster presentations include an analysis of the impact of CREON® (pancrelipase) on patient-reported daily symptoms in exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery NORTH CHICAGO, Ill. , Oct. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022, in Charlotte, N.C.

AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and nr-axSpA1-3 In a clinical study, RINVOQ delivered rapid and meaningful disease control based on patients achieving ASAS40 vs. placebo, as well as significant improvement in signs and symptoms of nr-axSpA at week 141,2 NORTH CHICAGO, Ill.

RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

It is well-known that AbbVie loses its US patent protection for Humira in 2023. Humira international sales have fallen sharply after already losing patent protection and the same will be expected in the US.

AbbVie: The Investor's Trifecta

Air Products and Chemicals

Chevron

There's no need to be anxious about investing in these high-quality stocks.

3 Dividend Aristocrats to Buy Right Now With No Hesitation

Moderna

Both companies are developing new drugs but that's where the similarities stop.

Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company's proprietary HEPTAD platform will extend AbbVie's current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond NORTH CHICAGO, Ill. , Oct. 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline

Tilray Brands

These two growth stocks should take very different trajectories as they expand.

Which Stock Is More Likely to 5X First: AbbVie or Tilray Brands?

Amazon

Intuitive Surgical

Texas Instruments

It's time to make a wishlist -- and just in time for the holidays!

4 Stocks I Own and Will Buy More of if the Market Crashes

Perry Siatis Named as Executive Vice President, General Counsel and Secretary NORTH CHICAGO, Ill. , Oct. 17, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that Laura J.

AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire

Abbott Labs

CVS Health

These ultra-reliable businesses could deliver quarterly payments that steadily grow throughout your retirement.

3 Dividend Stocks to Buy Now for a Lifetime of Passive Income

Federal Realty Investment Trust

Illinois Tool Works

Johnson & Johnson

Altria

The world is experiencing several crises at once, including a global energy shortage, high inflation, volatile markets, and the Russia-Ukraine war. In times like these, going with crisis-resistant, proven, reliable dividend payers could be a good idea.

News for AbbVie Stock (ABBV)